NEW YORK, Feb 15 – Variagenics said Thursday its fourth-quarter revenues jumped to $1.2 million, compared with $100,000 in the previous year while revenues for the year rose to $2.3 million from $400,000.

"The year 2000 was pivotal for Variagenics as we commercialized our proprietary technologies for identifying drug-specific genetic markers," Taylor Crouch, CEO of Variagenics, said in a statement. "We are pursuing a vision to place Variagenics' pharmacogenomics at the heart of a new generation of individualized drugs and companion diagnostics.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.